Inventiva vs Traws Pharma
IVA and TRAW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IVA and TRAW compare
Traws Pharma scores higher on the StockData Score (5 against 1 for Inventiva), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IVA | TRAW |
|---|---|---|
| Size and price | ||
| Market cap | – | $3.9M |
| Share price | $3.68 | $0.251 |
| Change, 1 year | −9.1% | −88.3% |
| Change, 5 years | −72.1% | −99.7% |
| Beta (5Y) | 0.83 | 1.19 |
| Employees | 77 | 7 |
| StockData Score | ||
| Total score | 1 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −51.3% | – |
| Revenue growth, 5Y average | 64.5% | 64.6% (better) |
| Profitability | ||
| Operating margin | −3146% | – |
| Financial health | ||
| Interest coverage | −0.7× | – |
| Current ratio | 3.81 (better) | 0.93 |
| Altman Z-score | – | −85.39 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −109% |
| Shareholder yield | – | −109% |
| Ownership | ||
| Held by institutions | 45.2% | 40.1% |
| Held by insiders | 24.7% | 35.7% |
| Insider net buying, 12 months | – | $998K |
| Short interest, % of float | – | 6.9% |
Go deeper
- IVA stock overview
- IVA income statement
- IVA valuation and score
- TRAW stock overview
- TRAW income statement
- TRAW valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.